ViCentra closes EUR 65M (USD 74M) Series C funding to expand the footprint of world’s smallest insulin pump across Europe
- New investor, Partners in Equity – joins existing investors Health Innovations, INKEF Capital LSP and Invest-NL
- Proceeds will be used for commercial European launch of updated Kaleido insulin patch pump system including automated insulin delivery (AID) or closed loop
December 16, 2021, Utrecht, The Netherlands – ViCentra, the company behind Kaleido, the world’s smallest and lightest wearable insulin pump (“patch pump”), announces the closing of a EUR 65 million (USD 74 million) Series C financing. The investment round was led by new investor Partners in Equity BV, the Amsterdam based Venture Capital firm with a long-term focus. Existing investors LSP, INKEF Capital and Health Innovations also participated in the investment.
